BioAtla, Inc. (BCAB)
| Market Cap | 2.89M -89.0% |
| Revenue (ttm) | 8.50M -22.7% |
| Net Income | -31.45M |
| EPS | -22.74 |
| Shares Out | 1.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,033,981 |
| Open | 1.580 |
| Previous Close | 3.140 |
| Day's Range | 1.510 - 2.100 |
| 52-Week Range | 1.510 - 71.500 |
| Beta | 0.76 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About BCAB
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3... [Read more]
Financial Performance
In 2025, BioAtla's revenue was $2.00 million, a decrease of -81.82% compared to the previous year's $11.00 million. Losses were -$59.61 million, -14.57% less than in 2024.
Financial StatementsNews
BioAtla Quarterly report: Q2 2026
BioAtla has published its Q2 2026 quarterly earnings report on August 13, 2026.
BioAtla Proxy statement: Proxy filing
BioAtla filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
BioAtla Proxy statement: Proxy filing
BioAtla filed a proxy statement on June 3, 2026, providing details for shareholder voting and corporate governance matters.
Context Therapeutics enters license agreement amendment with BioAtla
Context Therapeutics (CNTX) announced the amendment of the company’s exclusive license agreement, dated September 23, 2024, with BioAtla (BCAB). The amendment removes all future milestone and royalty ...
BioAtla Quarterly report: Q1 2026
BioAtla has published its Q1 2026 quarterly earnings report on May 15, 2026.
BioAtla trading halted, news pending
19:50 EDT BioAtla (BCAB) trading halted, news pending
BioAtla announces 50-for-1 share consolidation
BioAtla announced that it will effect a 50-for-1 share consolidation of its common stock, par value $0.0001 per share, that is expected to become effective on April 6 at 12:01…
BioAtla Announces Share Consolidation
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (...
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc....
BioAtla Annual report: Q4 2025
BioAtla has published its Q4 2025 annual report on March 31, 2026.
BioAtla Slides: Investor presentation
BioAtla has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (...
BioAtla Proxy statement: Proxy Filing
BioAtla filed a proxy statement on March 2, 2026, providing details for shareholder voting and corporate governance matters.
BioAtla Proxy statement: Proxy Filing
BioAtla filed a proxy statement on February 11, 2026, providing details for shareholder voting and corporate governance matters.
BioAtla Proxy statement: Proxy Filing
BioAtla filed a proxy statement on January 30, 2026, providing details for shareholder voting and corporate governance matters.
BioAtla Registration statement: Registration Filing
BioAtla filed a registration statement on January 16, 2026, providing details about a securities offering with the SEC.
BioAtla Proxy statement: Proxy Filing
BioAtla filed a proxy statement on January 15, 2026, providing details for shareholder voting and corporate governance matters.
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...
BioAtla Proxy statement: Proxy Filing
BioAtla filed a proxy statement on December 31, 2025, providing details for shareholder voting and corporate governance matters.
BioAtla Proxy statement: Proxy Filing
BioAtla filed a proxy statement on December 5, 2025, providing details for shareholder voting and corporate governance matters.
BioAtla Proxy statement: Proxy Filing
BioAtla filed a proxy statement on November 24, 2025, providing details for shareholder voting and corporate governance matters.
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...
BioAtla Earnings Call Transcript: Q3 2025
FDA alignment on phase III OSV trial and strong clinical data across programs highlight progress, with a strategic transaction expected by year-end. Cash position was $8.3M at quarter-end, with reduced R&D and G&A expenses and a $2M milestone payment received in October.
BioAtla Quarterly report: Q3 2025
BioAtla has published its Q3 2025 quarterly earnings report on November 13, 2025.
BioAtla Earnings release: Q3 2025
BioAtla released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.